Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Teva Pharmaceutical Industries ( TEVA) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.9%. By the end of trading, Teva Pharmaceutical Industries rose $0.56 (1.4%) to $39.80 on average volume. Throughout the day, 3,517,590 shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 4,162,300 shares. The stock ranged in a price between $39.24-$40.10 after having opened the day at $39.28 as compared to the previous trading day's close of $39.24. Other companies within the Health Care sector that increased today were: Alimera ( ALIM), up 22.2%, TearLab Corpoartion ( TEAR), up 17.3%, Escalon Medical Corporation ( ESMC), up 13.2% and Questcor Pharmaceuticals ( QCOR), up 13.1%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $33.1 billion and is part of the drugs industry. The company has a P/E ratio of 17.3, below the S&P 500 P/E ratio of 17.7. Shares are up 4.2% year to date as of the close of trading on Monday. Currently there are 11 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 15 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself.

On the negative front, Biota Pharmaceuticals ( BOTA), down 65.7%, Opexa Therapeutics ( OPXA), down 17.0%, Unilife Corporation ( UNIS), down 11.4% and Hooper Holmes ( HH), down 11.3% , were all laggards within the health care sector with Express Scripts ( ESRX) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.